Pharmacologic suppression of Caspase-2 as well as Caspase-2 disruption, observed in hepatocyte ER stress-associated NASH prevented fibrosis and inflammation by preventing SREBP1 and SREBP2 activation. Here, CASP2 is linked to metabolic dysfunction-associated steatohepatitis.